« GSK: More Cuts Coming |
Main
| A Pile of Malaria Leads For the Taking »
February 1, 2010
And on the Carl Icahn Front. . .
Posted by Derek
He's back with three more directors nominated for the company's board. There are two Icahnians there already, and this round of proxy voting will say a lot about whether shareholders think that taking Biogen down the road that Imclone went is a good thing or not. Stay tuned. . .
Comments (2)
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- › Academia and Industry, Suing Each Other
- › Let's Start Off the Meeting With An Ad, OK?
- › The Academic-Industrial Collaboration in Drug Discovery Panel: Today
- › Glass Structure, Atom by Atom
- › How the Andrulis Paper Got Published
- › AstraZeneca in Waltham
- › Fluorine NMR: Why Not?
- › AstraZeneca Layoffs and Closings
1. Hap on February 1, 2010 2:47 PM writes...
I prefer to think of Icahn like a viral infection rather than as a storm - storms do something good, after all.
"Your Icahn titer is increasing. I'm sorry."
Permalink to Comment2. Rman on February 3, 2010 1:22 PM writes...
With the departure of CEO Jim Mullen and earlier Cecill Pickett things look pretty bad for small molecule at Biogenidec.
Permalink to Comment